newsfilter
← Latest News
Business Wire·

Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update

Open Medicine AI Established as a Separate Company with Executed Commercial Licenses; Progression-Free Survival Benefit Deepens in EGFR Exon 21 L858R Lung Cancer with LP-300; EMA Clears LP-184, zirdafulven, for